JP2017526706A5 - - Google Patents

Download PDF

Info

Publication number
JP2017526706A5
JP2017526706A5 JP2017513199A JP2017513199A JP2017526706A5 JP 2017526706 A5 JP2017526706 A5 JP 2017526706A5 JP 2017513199 A JP2017513199 A JP 2017513199A JP 2017513199 A JP2017513199 A JP 2017513199A JP 2017526706 A5 JP2017526706 A5 JP 2017526706A5
Authority
JP
Japan
Prior art keywords
alkyl
cancer
tumor
cell
lymphoma
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017513199A
Other languages
English (en)
Japanese (ja)
Other versions
JP2017526706A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2015/049213 external-priority patent/WO2016040498A1/en
Publication of JP2017526706A publication Critical patent/JP2017526706A/ja
Publication of JP2017526706A5 publication Critical patent/JP2017526706A5/ja
Pending legal-status Critical Current

Links

JP2017513199A 2014-09-10 2015-09-09 イソオキサゾールカルボキサミド化合物 Pending JP2017526706A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462048759P 2014-09-10 2014-09-10
US62/048,759 2014-09-10
US201562146794P 2015-04-13 2015-04-13
US62/146,794 2015-04-13
PCT/US2015/049213 WO2016040498A1 (en) 2014-09-10 2015-09-09 Isoxazole carboxamide compounds

Publications (2)

Publication Number Publication Date
JP2017526706A JP2017526706A (ja) 2017-09-14
JP2017526706A5 true JP2017526706A5 (enExample) 2018-10-18

Family

ID=55459522

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017513199A Pending JP2017526706A (ja) 2014-09-10 2015-09-09 イソオキサゾールカルボキサミド化合物

Country Status (6)

Country Link
US (2) US10428029B2 (enExample)
EP (1) EP3193603A4 (enExample)
JP (1) JP2017526706A (enExample)
AU (1) AU2015315167A1 (enExample)
CA (1) CA2960274A1 (enExample)
WO (1) WO2016040498A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016040515A1 (en) * 2014-09-10 2016-03-17 Epizyme, Inc. Substituted piperidine compounds
JP2017527576A (ja) 2014-09-10 2017-09-21 エピザイム,インコーポレイティド 置換シクロヘキシルアミン化合物
WO2016040511A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamides as irreversible smyd inhibitors
KR102496364B1 (ko) 2014-09-10 2023-02-06 에피자임, 인코포레이티드 Smyd 억제제
JP6763380B2 (ja) 2015-06-17 2020-09-30 住友化学株式会社 有害節足動物防除剤
MA53645A (fr) * 2018-09-21 2021-12-29 Novartis Ag Composés d'isoxazole carboxamide et leurs utilisations
CN109879868B (zh) * 2019-03-07 2022-04-22 南通大学 含2-芳基噁唑结构的吡唑酰胺类化合物的制备和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3065225A (en) * 1960-02-05 1962-11-20 Hoffmann La Roche N', n4-di-isoxazolylcarbonyl-sulfanilamide derivatives
DE19930075A1 (de) * 1999-06-30 2001-01-04 Bayer Ag Neue Amino- und Amidosulfonamide als antivirale Mittel
GB0017518D0 (en) * 2000-07-17 2000-08-30 Merck Sharp & Dohme Therapeutic agents
US7259157B2 (en) * 2001-04-03 2007-08-21 Merck & Co., Inc. N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists
CA2449249A1 (en) * 2001-06-12 2002-12-19 Merck & Co., Inc. Nr2b receptor antagonists for the treatment or prevention of migraines
DE10306250A1 (de) * 2003-02-14 2004-09-09 Aventis Pharma Deutschland Gmbh Substituierte N-Arylheterozyklen, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
WO2005004810A2 (en) * 2003-07-02 2005-01-20 Merck & Co., Inc. Arylsulfonamide derivatives
US7709645B2 (en) * 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
WO2006067446A1 (en) * 2004-12-22 2006-06-29 Astrazeneca Ab Pyridine carboxamide derivatives for use as anticancer agents
US7291743B2 (en) * 2005-03-29 2007-11-06 Geneblue Corporation Isoxazole derivatives and methods of treating nitric oxide mediated diseases
NL2000284C2 (nl) * 2005-11-04 2007-09-28 Pfizer Ltd Pyrazine-derivaten.
WO2008040149A1 (en) * 2006-09-05 2008-04-10 Dexian Dou Composition and method for treating immune-mediated skin disorders
BRPI0810202A2 (pt) * 2007-05-03 2014-10-21 Pfizer Ltd Derivados de piridina
WO2008137834A2 (en) 2007-05-04 2008-11-13 Osi Pharmaceuticals, Inc. Crystal structure of smyd3 protein
CA2786438C (en) * 2010-01-29 2015-10-13 Hanmi Science Co., Ltd. Thieno[3,2-d]pyrimidine derivatives having inhibitory activity on protein kinases
WO2013043826A1 (en) * 2011-09-21 2013-03-28 Abbvie Inc. Tricyclic compounds useful as protein kinase inhibitors
WO2014100157A1 (en) * 2012-12-18 2014-06-26 Alcyone Lifesciences, Inc. Systems and methods for reducing or preventing backflow in a delivery system
AU2014237312B2 (en) * 2013-03-15 2019-03-28 Shifa Biomedical Corporation Anti-proprotein convertase subtilisin kexin type 9 (anti-PCSK9) compounds and methods of using the same in the treatment and/or prevention of cardiovascular diseases
WO2016040511A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Isoxazole carboxamides as irreversible smyd inhibitors
US20170253601A1 (en) * 2014-09-10 2017-09-07 Epizyme, Inc. Substituted Pyrrolidine Compounds
KR102496364B1 (ko) 2014-09-10 2023-02-06 에피자임, 인코포레이티드 Smyd 억제제
WO2016040508A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Substituted pyrrolidine carboxamide compounds
JP2017527576A (ja) 2014-09-10 2017-09-21 エピザイム,インコーポレイティド 置換シクロヘキシルアミン化合物
WO2016040515A1 (en) 2014-09-10 2016-03-17 Epizyme, Inc. Substituted piperidine compounds

Similar Documents

Publication Publication Date Title
JP2017526706A5 (enExample)
JP2017528464A5 (enExample)
JP2016514695A5 (enExample)
JP2017527577A5 (enExample)
JP2017528460A5 (enExample)
JP2017538659A5 (enExample)
JP2019514950A5 (enExample)
JP2017527576A5 (enExample)
RU2014112345A (ru) Хинолил-содержащее соединение гидроксамовой кислоты, способ его получения, фармацевтическая композиция, содержащая это соединение, и его применение
CN103402519B (zh) 肿瘤治疗剂
JP2020515571A5 (enExample)
JP2017510641A5 (enExample)
CA3094449A1 (en) Combination product of bcl-2 inhibitor and mdm2 inhibitor and use thereof in the prevention and/or treatment of diseases
JP2013064024A5 (enExample)
IL272697B2 (en) A polymorphic form of TG02
JP2017528461A5 (enExample)
HRP20211877T1 (hr) Spojevi n-(4-hidroksi-4-metil-cikloheksil)-4-fenil-benzensulfonamida i n-(4-hidroksi-4-metil-cikloheksil)-4- (2-piridil)-benzensulfonamida i njihova terapijska uporaba
JPWO2021188948A5 (enExample)
RU2017124371A (ru) Комбинация производного 6-оксо-1,6-дигидро-пиридазина, обладающего противораковой активностью, с производным хиназолина
JP2020506884A5 (enExample)
JP2016106092A (ja) 組合せ
HK1259409A1 (zh) 酪蛋白激酶1δ在乳腺癌中的治疗靶向
CA2994456A1 (en) Benzodiazepines as bromodomain inhibitors
TN2010000139A1 (en) Organic compounds
CN109476650A (zh) 五元杂环类化合物及其制备方法、药物组合物和用途